About Us

Why FlowCell?

Who Am I And My Journey So Far?

Hello all, I am Max, founder, and CEO of FlowCell. I did my Ph.D. in Biochemistry at Harvard University and continued as a Postdoc at Baylor University. Later, I took up the role of a Senior Scientist in Abott, Principal scientist at Instrumentation Laboratory, and Director of Assay development, mainly in cancer and biomarker research. This included microfluidics and lab instrumentation. Finally, I started my own company, FlowCell, which had always been my dream.

The Problems

Having worked in both academic institutions and industry in different roles, I realized there were, and still are, many problems that need addressing. On one hand, there are regulatory or structural challenges, and on the other hand, there are technical obstacles to overcome. Both these affect the pace of innovation in healthcare and life sciences as well. They further impact the speed at which they have realized to final outcomes.

The Problem

Thereby the benefit to the general public who are denied these innovations and healthcare options at the right time. Another major issue that currently plagues research either in Pharmaor academia is the access to the evolving next-generation technology and experimental models (not animal models) that mimic human physiology.

The Vision

My desire to provide the right tools and opportunities to both academia and industry has culminated in FlowCell. Technology and research are on parallel paths of evolution, which leaves a huge gap of awareness between them. The current COVID-19 pandemic has made this wide gap obvious between research models and technology.

The Problem

FlowCell aims to bridge this gap, create awareness on tools & technology, applications in various fields like cancer, single-cell analysis, microfluidics to mimic human physiology and translate results into meaningful outcomes faster for the benefit of society.

We also envision bringing the patient community on to a common platform to create a huge patient-oriented database. This platform is where the patients share their condition and data, especially those with challenging and rare diseases. It will be open to all patients empowering them to make informed decisions and take control of their health.

The Approaches

We will follow a two-prong approach to address these two concerns:

1. Fluids for Life (FFL):

FFL is a marketplace of tools and cutting-edge technologies for drug development and Personalized medicine. FlowCell will not just market the technology, but also be a source of knowledge for the tools it provides and their applications in different areas. These areas include cancer, drug discovery, models mimicking clinical situations in the lab, etc., and networking between institutes and technology providers to quicken the Bed-to Bedside process. This will create a unique ecosystem of a niche technology.

2. Health Sherlock:

This platform will be an open-to-all noncommercial database for all the patients suffering from various diseases, especially those with rare and uncommon diseases or conditions. The idea is to create an ecosystem for patients to save their health data, get information based on their condition, tests, diagnosis, and possible treatment or therapy options. This data can be accessed by authorized healthcare professionals to offer better help to patients. It will create awareness and provide information on rare diseases closer to patients and hopefully improve their quality of life.

Create awareness to bring people together and fight for a common cause, a better quality of life.

Health Sherlock benefits

The Opportunity

The market potential of this opportunity is huge. It has increased investments in cancer, single-cell, 3D cultures, drug discovery in improved models, and reduction in animal experimentation (NA3RsC).

Healthcare is 10% of global GDP, topping 17% in the U.S.A. We estimate the total market for precision medicine to be at least 10% of total healthcare spending, or $1 trillion. Our core market for 3-dimensional biology in a dish that recapitulates human physiology is growing at 25% CAGR and will continue to increase.

FlowCell is not just about making money. We have a profound commitment to ethics for all our interactions with partners, patients, employees, and investors.

FlowCell is committed to transparency and fairness. We believe in open-platform development. I believe this service is our responsibility to society.